A type of cell therapy called the T-cell Amiga receptor (CAR-T) is a novel method for the destruction of cancer cells. The cell therapy method in which live cells are transmitted to the patient’s body is not a new method, in which scientists have succeeded in planting bone marrow cells within the human body over the past sixties, passing over a century of blood transfusion. Now in the forefront of the typology, a new method is invented that the patient’s own tissue is reprogrammed to fight cancer at the cellular level.
But in the new method (CAR-T), the T-cell is removed from the body and genetically modified to fight cancer. In the past five years, clinical trials of hard and advanced specimens have yielded successful results, especially with regard to leukemia, with a response rate of 90% to some types of leukemia.
Several clinical trials are under way for various types of cancer, and the FDA’s admission process has been rapidly expanding to treat acute lymphoblasts and progressive b-lymphoma. If everything goes well, this cell-therapies will go on sale next year.
While treatment with this method is in its earliest days, it will be a problem in the future. At present, the production of a therapeutic approach is complex and time-consuming. Reggie Smith, a member of the drug team and responsible for optimizing this technique, said that Tactile isolation requires a method called Lukefours. After isolation, T-cells are transferred to the factory for a period of two to three weeks to undergo a genetic modification and are transmitted to the nearest treatment center for transmission to the patient’s body.
In this case, it is necessary not only several steps to re-plan the cells, but also to prevent contamination and destruction, and tough measures that add to the complexity and cost of the cost.
At present, the time to return to the vessel according to the type of technique used is about 2 to 4 weeks, but the increasing need for this therapeutic approach to pharmaceutical companies is to invent new methods for rapid and cost-effective production.
GE, one of Big Pharma’s business partners, has been successful in integrating years of experience in the field of pharmaceuticals and robust industrial hardware and software. The use of new methods will not only increase the speed of production, but also make it safer than ever before.
Smith added that this process of mechanization should continue to minimize human error. Because this drug is complex and there are new examples that can affect the quality and safety of the product. As soon as a reliable method of treatment for various diseases is provided.
Shengnan Yu, Anping Li, Qian Liu, Journal of Hematology & Oncology201710:78, DOI: 10.1186/s13045-017-0444-9